Alvotech Holdings S.A Logo

Alvotech Holdings S.A

Develops and manufactures affordable biosimilar medicines for global patient access.

ALVO | LU

Overview

Corporate Details

ISIN(s):
LU2458332611
LEI:
222100DCZBOWV5DZ8372
Country:
Luxembourg
Address:
9, RUE DE BITBOURG, L-1273 LUXEMBOURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alvotech is a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines. The company's mission is to improve lives by increasing patient access to high-quality, affordable biologic treatments worldwide. Alvotech operates a vertically integrated platform, managing the entire process from cell line development to fill-and-finish manufacturing. This end-to-end approach provides control, scale, and speed in its development and production processes. For global commercialization, the company forms strategic partnerships with third parties to market and distribute its robust pipeline of biosimilars to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-24 11:30
Regulatory Filings
Markaðsleyfi veitt á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu Alvotech v…
Icelandic 8.4 KB
2025-11-24 11:30
Regulatory Filings
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denos…
English 13.3 KB
2025-11-20 10:00
Regulatory Filings
Alvotech og Advanz Pharma fá markaðsleyfi á Evrópska efnahagssvæðinu fyrir Gobi…
Icelandic 7.4 KB
2025-11-20 10:00
Regulatory Filings
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Econo…
English 13.7 KB
2025-11-12 22:40
Earnings Release
Alvotech kynnir uppgjör fyrstu níu mánaða ársins 2025 og helstu áfanga í rekstr…
Icelandic 24.6 KB
2025-11-12 22:40
Earnings Release
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Busin…
English 29.2 KB
2025-11-10 10:00
Legal Proceedings Report
Alvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AV…
Icelandic 7.9 KB
2025-11-10 10:00
Legal Proceedings Report
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market …
English 10.3 KB
2025-11-06 15:00
Regulatory Filings
Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu …
Icelandic 7.2 KB
2025-11-06 15:00
Regulatory Filings
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Bio…
English 16.4 KB
2025-11-04 22:01
Report Publication Announcement
Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekst…
Icelandic 3.7 KB
2025-11-04 22:01
Report Publication Announcement
Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for…
English 5.9 KB
2025-11-02 23:10
Legal Proceedings Report
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05…
Icelandic 6.4 KB
2025-11-02 23:10
Regulatory Filings
Alvotech Provides Update on the Status of U.S. Biologics License Application fo…
English 7.6 KB
2025-10-22 11:00
Board/Management Information
Skipulagsbreytingar á viðskiptasviði Alvotech
Icelandic 6.6 KB

Automate Your Workflow. Get a real-time feed of all Alvotech Holdings S.A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alvotech Holdings S.A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alvotech Holdings S.A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xcell Therapeutics Inc. Logo
Develops serum-free media & automated systems for cell therapy & regenerative medicine.
South Korea
373110
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenetic Biosciences, Inc. Logo
Advancing DNase & CAR T immune-oncology platforms to treat hard-to-treat cancers.
United States of America
XBIO
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
XORTX Therapeutics Inc. Logo
Developing late-stage, uric acid-lowering therapies for gout and progressive kidney disease.
United States of America
XRTX
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
Israel
XTLB

Talk to a Data Expert

Have a question? We'll get back to you promptly.